Madam Chair and honourable standing committee members, thank you for the opportunity to appear before you today.
As noted, I'm the director of Partnership for Women's Health Research Canada, which unites the Women's Health Research Institute in B.C., the Women & Children's Health Research Institute in Alberta, Women's College Hospital in Ontario, and IWK Health.
On behalf of the partnership, I would like to make three points about how diversity and inclusion in research and science contribute to research excellence.
First, ensuring diversity and inclusion in research populations is critical for research relevance. For example, in health, some pain medications work better if you have one X chromosome, male, rather than two X chromosomes, female. We now know that individual cells have a sex, thus treatments need to be tailored accordingly, such as treatments for pain. Over a four-year period in the United States, eight out of 10 drugs that were withdrawn from the market were because of negative side effects in women. That was because not enough females were included in the trials that led to approval.
One of these drugs, Prepulsid, was withdrawn because it caused irregular heartbeats, arrhythmias, more frequently in women. This drug caused the death of Vanessa Young, a 15-year-old Canadian. It resulted in Vanessa's Law, which aims to improve post-market drug surveillance and increase transparency about who was included in clinical trials.
If we're to move beyond and prevent health harms because of sex differences before they occur, as in the tragic case of Vanessa, sex differences must be studied. In Canada, research excellence requires an increase from the current 7% of health research dollars allocated to women's health research and greater accountability for sex and gender analysis and reporting.
Canada is a global policy leader in promoting sex and gender health research, but we need to increase accountability by researchers for the commitments they make at the research proposal stage. Recommendations that we make align with greater calls for grant monitoring made by other expert witnesses.
In our written brief, we make concrete recommendations, including establishing a public repository of all published findings for funded projects; sex, gender, and ethnicity of study participants should be reported in all studies and publications; and funding applications should include a section where applicants are required to report on sex and gender results from previous government funded research.
Second, as noted by others, socio-demographic diversity within research teams is associated with research excellence, when we look at novel research questions and higher research output. This committee has discussed viewpoint diversity. We know that our viewpoints and the research questions we ask are influenced by our personal experiences and background. To illustrate, Black scientists are more likely to study health disparities than white scientists. Female scientists are more likely to study research questions that use female and male sex in all research. Diverse scientists asking and answering relevant questions, and working together in research groups that include people of different genders and ethnicities, contribute to research excellence.
In the science and research environment, there is exhaustively documented inequitable treatment of females and people of colour. Programs to increase equity in science and research can increase fairness and diversity, without undermining merit-based evaluation. In Canada, before the introduction of the equity mandates for the Canada research chairs, the vast majority of nominees were senior male candidates, and other merit-based applications were not included in the competitions.
The government, by changing the requirements of inclusion, increased the diversity of candidates, but did not change the excellence of the candidates, as measured by peer-reviewed publications, science communication, book chapters, patents or policies. The CRC program is still a meritocracy. Increased diversity results in better, more impactful science that, ultimately, improves the lives of Canadians.
Third, to assess research excellence, we should focus on scientific content and impact to patients, families, and communities, rather than number of publications and journal impact factors. When the research improves outcomes, implements health technology or evaluates health system change across a diverse population, the impact is then sustainable and generalizable to all Canadians.
Investing in women's health research and integration of sex and gender across care and innovation can make Canada a magnet for the world's top scientists and entrepreneurs and also lower costs through better evidence-based prevention and treatment for all Canadians, helping them get ahead.
Thank you very much.